Actemra80 mg/4 ml

Actemra is a recombinant humanized monoclonal antibody that blocks the interleukin-6 (IL-6) receptor. It is used for the following indications:

Established / approved uses

• Rheumatoid arthritis (RA): Moderately to severely active RA in adults who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs), typically used in combination with methotrexate or as monotherapy.
• Polyarticular juvenile idiopathic arthritis (PJIA): Active PJIA in patients 2 years of age and older.
• Systemic juvenile idiopathic arthritis (SJIA): Active SJIA in patients 2 years of age and older.
• Giant cell arteritis (GCA): Treatment of adults with giant cell arteritis, usually combined with a tapering glucocorticoid course.
• Cytokine release syndrome (CRS): Severe or life-threatening CRS associated with chimeric antigen receptor (CAR) T-cell therapy, in patients 2 years and older.
• COVID-19: Hospitalized adults and children 2 years and older who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) — used as an adjunct to standard of care, not as monotherapy.

Guideline-supported / adjunct use

• Systemic sclerosis-associated interstitial lung disease (SSc-ILD): To slow the rate of decline in pulmonary function in adults.

Because Actemra is a biologic agent with a boxed warning for serious infection, it should be prescribed and monitored only by a physician experienced in its use.

Each vial/syringe of Tocilizumab contains tocilizumab as the active ingredient, formulated for either intravenous infusion or subcutaneous injection. Common presentations include intravenous concentrate for solution for infusion (e.g., 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL vials) and subcutaneous prefilled syringe/autoinjector (e.g., 162 mg/0.9 mL). Excipients typically include polysorbate 80, sucrose, and a buffering system; formulations vary by manufacturer, so the product leaflet should be checked for exact excipient content.

Actemra is a genetically engineered, humanized monoclonal antibody of the IgG1 subclass that targets the interleukin-6 receptor (IL-6R). Interleukin-6 is a pro-inflammatory cytokine implicated in the pathogenesis of several autoimmune and hyperinflammatory conditions, including rheumatoid arthritis and cytokine release syndrome. By binding to both soluble and membrane-bound IL-6 receptors, Actemra inhibits IL-6-mediated signaling and reduces downstream inflammatory activity. It is administered parenterally, either as an intravenous infusion or a subcutaneous injection, and is used under specialist supervision for chronic inflammatory joint diseases, vasculitis, and acute hyperinflammatory states.

Actemra belongs to the therapeutic class of interleukin-6 (IL-6) receptor antagonists, a subgroup of biologic disease-modifying antirheumatic drugs (bDMARDs). It is classified as an immunomodulatory/immunosuppressive monoclonal antibody.

Tocilizumab binds specifically to both soluble and membrane-bound interleukin-6 receptors (sIL-6R and mIL-6R), inhibiting IL-6-mediated signal transduction through these receptors. IL-6 is a multifunctional cytokine produced by various cell types including T-cells, B-cells, monocytes, and fibroblasts, and it plays a role in T-cell activation, immunoglobulin secretion, hepatic acute-phase protein production (e.g., C-reactive protein, serum amyloid A, fibrinogen), and stimulation of hematopoietic stem cell proliferation and differentiation. Elevated IL-6 levels are found in the synovial fluid of patients with rheumatoid arthritis and correlate with disease activity. By blocking IL-6 signaling, Tocilizumab reduces synovial inflammation, acute-phase reactant levels, and systemic inflammatory symptoms such as fever.

Pharmacokinetics

• Absorption: After subcutaneous injection, peak plasma concentrations are reached in approximately 2–5 days; bioavailability is approximately 80%.
• Distribution: Small volume of distribution, consistent with limited extravascular distribution.
• Metabolism/Elimination: Cleared through both linear (non-saturable) and non-linear (target-mediated, saturable) pathways; elimination half-life is concentration-dependent, ranging from a few days at low concentrations up to approximately 11–13 days at steady state with intravenous dosing.

Actemra intravenous infusion must be diluted and administered by a healthcare professional over 60 minutes using an infusion set with an in-line filter; it should not be given as an intravenous push or bolus. Subcutaneous injections are given into the thigh or abdomen, rotating injection sites, and should not be injected into skin that is tender, bruised, red, or hard. Patients or caregivers may self-administer subcutaneous Actemra after proper training. Do not shake the syringe/autoinjector. Prior to each administration, patients should be assessed for signs of active infection.

Actemra has clinically significant interactions related to its immunosuppressive and IL-6-blocking effects:

• Other biologic DMARDs / immunosuppressants (e.g., TNF antagonists, anti-CD20 agents, IL-1 receptor antagonists, other biologic RA therapies): Concurrent use with Actemra is not recommended due to an increased risk of serious infection from additive immunosuppression.
• Live and live-attenuated vaccines: Should not be given concurrently with Actemra, as immunosuppression may reduce vaccine efficacy or cause vaccine-associated infection; all recommended vaccinations should be brought up to date before starting therapy.
• CYP450 substrate drugs (e.g., warfarin, cyclosporine, theophylline, statins, oral contraceptives): IL-6 suppresses CYP450 enzyme expression; by normalizing IL-6 activity, Actemra can increase CYP450 enzyme activity, potentially lowering plasma levels and efficacy of these drugs. Dose adjustment and monitoring (e.g., INR for warfarin) may be needed, particularly in the weeks following initiation or discontinuation of Actemra.

The most commonly reported adverse effects of Actemra (occurring in ≥5% of patients) include:

• Upper respiratory tract infections and nasopharyngitis
• Headache
• Hypertension
• Elevated liver transaminases (ALT/AST)
• Injection site reactions (with subcutaneous use)
• Increased blood cholesterol and triglycerides

Less common but serious effects

• Serious infections (bacterial, fungal, viral, opportunistic, including tuberculosis reactivation) — see Precautions and Warnings
• Gastrointestinal perforation, especially in patients with a history of diverticulitis
• Neutropenia and thrombocytopenia
• Hepatotoxicity, including rare severe drug-induced liver injury
• Infusion-related or injection-site hypersensitivity reactions, including rare anaphylaxis

Pregnancy: Animal reproduction studies with Actemra have shown an increased risk of fetal loss/miscarriage at high doses. There are no adequate and well-controlled studies in pregnant women. Actemra should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus, and only under close medical supervision.

Lactation: It is not known whether Actemra is excreted in human milk, though human IgG is known to be present in breast milk. A decision should be made to discontinue breastfeeding or discontinue Actemra, taking into account the benefit of breastfeeding to the infant and the benefit of therapy to the mother, in consultation with a physician.

Boxed Warning: Serious Infections

Patients treated with Actemra are at increased risk of developing serious infections that may lead to hospitalization or death, including tuberculosis (TB) reactivation, invasive fungal infections (e.g., candidiasis, pneumocystosis, aspergillosis), bacterial infections, and other opportunistic pathogens. Patients should be screened for latent TB before starting treatment and monitored for signs of infection throughout therapy; treatment should be interrupted if a serious infection develops.

Other precautions

• Gastrointestinal perforation: Use with caution in patients with a history of diverticulitis or concurrent use of NSAIDs or corticosteroids, which may increase risk; evaluate promptly any new abdominal symptoms.
• Hepatic effects: Elevations in liver enzymes are common; obtain baseline liver function tests and monitor periodically (e.g., every 4–8 weeks during the first months, then as clinically indicated). Avoid initiation in patients with elevated transaminases or active liver disease.
• Hematologic effects: May cause neutropenia and thrombocytopenia; obtain baseline complete blood count and monitor periodically (e.g., 4–8 weeks after starting, then every 3 months).
• Lipid abnormalities: Increases in total cholesterol, LDL, HDL, and triglycerides may occur; obtain a baseline lipid panel and reassess approximately 4–8 weeks after starting, then periodically, managing per standard cardiovascular risk guidelines.
• Vaccinations: Avoid live vaccines during treatment; update all vaccinations per current guidelines before initiating Actemra.
• Hypersensitivity reactions: Anaphylaxis and other serious hypersensitivity reactions have occurred; administer only in a setting equipped to manage such reactions.
• Demyelinating disorders: Use caution in patients with a history of demyelinating disease, as cases have been reported.

There is limited clinical experience with overdosage of Actemra. In the event of a suspected overdose, the patient should be closely monitored for signs and symptoms of adverse effects, particularly signs of infection, and should seek immediate medical attention. There is no specific antidote; management is supportive and symptomatic. Contact a physician, hospital emergency department, or poison control center immediately if an overdose is suspected.

Store Actemra vials and prefilled syringes/autoinjectors refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the container in the outer carton in order to protect from light. Do not shake. Keep out of reach of children. Do not use beyond the expiry date printed on the pack.

Renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment; Actemra has not been formally studied in severe renal impairment, so caution and monitoring are advised.

Hepatic impairment: Has not been formally studied in patients with active hepatic disease or hepatic impairment; because Actemra can itself elevate liver enzymes, it should not be initiated in patients with active liver disease or hepatic impairment (see Precautions and Warnings).

Elderly: No overall differences in safety were observed between elderly and younger adult patients in clinical trials, but elderly patients may have a higher baseline incidence of infection, so use with appropriate caution.

Immunocompromised patients: Use with caution given the increased risk of serious infection; screening for latent infections (TB, viral hepatitis) is required before starting.

Duration of Actemra therapy depends on the indication and clinical response. In chronic conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and giant cell arteritis, treatment is typically long-term and continued as long as clinical benefit is observed and no unacceptable toxicity occurs, with periodic reassessment by the treating physician. For acute conditions such as cytokine release syndrome or COVID-19, treatment is typically limited to one to a maximum of four doses over a short period, as directed by the treating physician.

Intravenous Actemra concentrate must be diluted before use: the calculated dose is withdrawn from the vial and further diluted into a 100 mL bag of 0.9% sodium chloride injection to a final volume of 100 mL, using aseptic technique; the diluted solution should be gently inverted to mix (not shaken) and administered promptly. Subcutaneous prefilled syringes/autoinjectors are ready to use and do not require reconstitution or dilution.

Tocilizumab is classified as a monoclonal antibody, specifically an interleukin-6 (IL-6) receptor antagonist, within the broader category of biologic disease-modifying antirheumatic drugs (bDMARDs) / immunomodulatory agents.

Tocilizumab works by binding selectively to both soluble and membrane-bound interleukin-6 receptors (IL-6R), thereby blocking IL-6 from binding to its receptor and inhibiting the downstream signal transduction cascade mediated through gp130. Since IL-6 drives many of the inflammatory processes seen in rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome — including acute-phase protein production, B-cell and T-cell activation, and osteoclast activity — this blockade reduces inflammation, joint damage, and systemic inflammatory symptoms such as fever and elevated CRP.

Actemra is approved for use in children 2 years of age and older for polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome associated with CAR T-cell therapy, and COVID-19 requiring supplemental oxygen or ventilatory support, using weight-based dosing (see Dosage and Administration). Safety and efficacy in children younger than 2 years have not been established, and Actemra should not be used in this age group outside of these established indications. Growth and development, as well as vaccination status, should be monitored in pediatric patients receiving long-term therapy.